Big Pharma Split Corp.
PRM.TO
TSX
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 1.01M | 1.03M | 264.30K | 268.10K | -148.30K |
| Total Revenue | 1.01M | 1.03M | 264.30K | 268.10K | -148.30K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.01M | 1.03M | 264.30K | 268.10K | -148.30K |
| SG&A Expenses | 108.50K | 110.20K | 111.40K | 113.00K | 102.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 24.60K | 25.00K | 17.10K | 17.30K | 21.90K |
| Total Operating Expenses | 133.20K | 135.20K | 128.50K | 130.30K | 124.50K |
| Operating Income | 881.30K | 894.50K | 135.80K | 137.80K | -272.80K |
| Income Before Tax | 452.90K | 459.70K | -28.70K | -29.10K | -211.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 452.90K | 459.70K | -28.70K | -29.10K | -211.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 452.90K | 459.70K | -28.70K | -29.10K | -211.10K |
| EBIT | 881.30K | 894.50K | 135.80K | 137.80K | -272.80K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.39 | 0.40 | -0.02 | -0.02 | -0.17 |
| Normalized Basic EPS | 0.24 | 0.25 | -0.02 | -0.02 | -0.11 |
| EPS Diluted | 0.39 | 0.40 | -0.02 | -0.02 | -0.17 |
| Normalized Diluted EPS | 0.24 | 0.25 | -0.02 | -0.02 | -0.11 |
| Average Basic Shares Outstanding | 1.16M | 1.16M | 1.19M | 1.19M | 1.25M |
| Average Diluted Shares Outstanding | 1.16M | 1.16M | 1.19M | 1.19M | 1.25M |
| Dividend Per Share | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 |
| Payout Ratio | 85.63% | 85.63% | -1,267.93% | -1,267.93% | -197.24% |
